Absolute change in FACT-An scores from baseline among patients who achieved RBC-TI for ≥ 26 weeks in the placebo group at week 12 (before crossover) and the lenalidomide (LEN) 5 mg and 10 mg treatment groups at weeks 12, 24, 36, and 48 (safety population). MCID indicates minimal clinically important difference.